Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Irish development plans "safe" despite efficiency drive:

This article was originally published in Clinica

Executive Summary

The Irish government has given reassurances that a package of measures aimed at improving the efficiency of its health service will not affect current development plans, after announcing yesterday (July 17) that it would reduce by 800 the planned 6,000 increase in healthcare workers in 2002. The measure will have "minimal impact" on patient services, says the government, following a 50% increase in healthcare workforce since 1997 to over 90,000. Other measures include increases from August 1 in the statutory inpatient charge by E3 ($3) to E36 per overnight or day case to a maximum of E360 in any year, and in the cost of private and semi-private accommodation.

You may also be interested in...



RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

 

 

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Topics

UsernamePublicRestriction

Register

MT067422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel